RedHill Biopharma (RDHL) Cash from Operations (2012 - 2022)

RedHill Biopharma (RDHL) has 11 years of Cash from Operations data on file, last reported at 2421000.0 in Q4 2022.

• On a quarterly basis, Cash from Operations rose 83.71% year-over-year to 2421000.0 in Q4 2022; TTM through Dec 2022 was 29185000.0, a 55.13% increase from a year earlier, with the FY2025 full-year figure at 9651000.0, down 3.01% from the prior year.
• Cash from Operations for Q4 2022 stood at 2421000.0, up from 6028000.0 in the prior quarter.
• Over the last five years, Cash from Operations for RDHL reached as high as 2421000.0 in Q4 2022 and fell as low as 19025000.0 in Q3 2021.
• Historically, Cash from Operations has averaged 10848650.0 across 5 years, with a median of 9974500.0 in 2018.
• Across the five-year window, Cash from Operations slumped 107.45% in 2021 and soared 83.71% in 2022, its largest moves.
• Year by year, Cash from Operations stood at 8194000.0 in 2018, then plunged by 69.26% to 13869000.0 in 2019, then advanced by 8.39% to 12705000.0 in 2020, then declined by 16.95% to 14859000.0 in 2021, then surged by 83.71% to 2421000.0 in 2022.
• Per Business Quant data, the three most recent Cash from Operations figures were 2421000.0 in Q4 2022, 6028000.0 in Q3 2022, and 16581000.0 in Q2 2022.